$
335.120
+4.28(1.294%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
336.020
Open
330.310
VWAP
333.30
Vol
431.49K
Mkt Cap
23.59B
Low
327.8637
Amount
143.81M
EV/EBITDA(TTM)
48.57
Total Shares
70.04M
EV
24.00B
EV/OCF(TTM)
47.39
P/S(TTM)
10.40
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Show More
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
677.30M
+24.53%
1.147
+27.48%
728.28M
+21.89%
1.338
+16.36%
693.13M
+21.82%
1.148
+12.56%
Estimates Revision
The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 4% over the past three months. During the same period, the stock price has changed by 8.92%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.99%
In Past 3 Month
Stock Price
Go Up
up Image
+8.92%
In Past 3 Month
18 Analyst Rating
up
7.42% Upside
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 360.00 USD with a low forecast of 300.00 USD and a high forecast of 415.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
up
7.42% Upside
Current: 335.120
sliders
Low
300.00
Averages
360.00
High
415.00
Oppenheimer
NULL -> Outperform
initiated
$324 -> $365
2025-09-08
Reason
Oppenheimer assumed coverage of Insulet with an Outperform rating and price target of $365, up from $324. The firm updated the company's model post the Q2 report. Insulet has several new near-term catalysts, including the launch of its Omnipod 5 insulin pump and international expansion, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$266 -> $300
2025-08-21
Reason
Barclays raised the firm's price target on Insulet to $300 from $266 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect management's commentary and updated 2025 outlook.
Canaccord
Buy
maintain
$331 -> $353
2025-08-08
Reason
Canaccord raised the firm's price target on Insulet to $353 from $331 and keeps a Buy rating on the shares. The firm said Insulet beat revenue estimates across the board and confidently raised its guidance for FY25, with strength expected across all markets and populations.
RBC Capital
Outperform
maintain
$330 -> $350
2025-08-08
Reason
RBC Capital raised the firm's price target on Insulet to $350 from $330 and keeps an Outperform rating on the shares. The firm cites the company's Q2 earnings beat and revenue beat along with Q3 guidance that was well above consensus with its best-in-class product offering, market access, and execution, the analyst tells investors in a research note. Insulet is attractively positioned ahead as it continues to gain market share and furthers growth in a highly underpenetrated market as its catalysts continue to play out, the firm added.
Baird
Outperform
maintain
$350 -> $360
2025-08-08
Reason
Baird raised the firm's price target on Insulet to $360 from $350 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which reaccelerating growth and a growing competitive advantage.
Jefferies
Buy
maintain
$360 -> $375
2025-08-07
Reason
Jefferies raised the firm's price target on Insulet to $375 from $360 and keeps a Buy rating on the shares. The company's Q2 report came in well ahead of estimates, which led to a guidance raise across the board, the analyst tells investors in a research note. The firm upped estimates on the "outstanding" quarter.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Insulet Corp (PODD.O) is 67.01, compared to its 5-year average forward P/E of 184.80. For a more detailed relative valuation and DCF analysis to assess Insulet Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
184.80
Current PE
67.01
Overvalued PE
302.25
Undervalued PE
67.34

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
66.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
95.84
Undervalued EV/EBITDA
37.26

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.30
Current PS
0.00
Overvalued PS
15.27
Undervalued PS
7.34
Financial AI Agent

Financials

Annual
Quarterly
FY2025Q2
YoY :
+32.88%
649.10M
Total Revenue
FY2025Q2
YoY :
+121.79%
121.10M
Operating Profit
FY2025Q2
YoY :
-88.07%
22.50M
Net Income after Tax
FY2025Q2
YoY :
-87.64%
0.32
EPS - Diluted
FY2025Q2
YoY :
+179.81%
173.20M
Free Cash Flow
FY2025Q2
YoY :
+2.85%
69.67
Gross Profit Margin - %
FY2025Q2
YoY :
+80.26%
16.62
FCF Margin - %
FY2025Q2
YoY :
-91.01%
3.47
Net Margin - %
FY2025Q2
YoY :
-52.35%
10.04
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
946.5K
USD
3
3-6
Months
2.9M
USD
4
6-9
Months
4.0M
USD
2
0-12
Months
1.6M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
36.7K
Volume
1
3-6
Months
195.5K
Volume
3
6-9
Months
267.0K
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
135.7K
Volume
Months
6-9
6
483.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AI Stock Picker

PODD News & Events

Events Timeline

2025-09-16 (ET)
2025-09-16
07:10:48
Insulet anticipates Q3 revenue growth surpassing 22%-25% expectations.
select
2025-09-16
07:08:35
Insulet's CFO Ana Maria Chadwick to Depart, Flavia Pease to Take Over
select
2025-08-25 (ET)
2025-08-25
17:03:02
Insulet elevates Eric Benjamin to Chief Operating Officer and appoints Manoj Raghunandanan as Chief Growth Officer.
select
Sign Up For More Events

News

8.0
09-22NASDAQ.COM
Options Trading for Insulet (PODD) in the First Week of November 21st
4.5
09-22MarketWatch
15 Stocks Outperforming the S&P 500 This Year While Becoming More Affordable
4.0
09-18NASDAQ.COM
FELG's Core Assets Suggest a 10% Upside Potential
Sign Up For More News

FAQ

arrow icon

What is Insulet Corp (PODD) stock price today?

The current price of PODD is 335.12 USD — it has increased 1.29 % in the last trading day.

arrow icon

What is Insulet Corp (PODD)'s business?

arrow icon

What is the price predicton of PODD Stock?

arrow icon

What is Insulet Corp (PODD)'s revenue for the last quarter?

arrow icon

What is Insulet Corp (PODD)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Insulet Corp (PODD)'s fundamentals?

arrow icon

How many employees does Insulet Corp (PODD). have?

arrow icon

What is Insulet Corp (PODD) market cap?